Global scale upsell Clinisys serves a broad base of labs across multiple verticals and geographies, with plans to expand into biotech and pharma. The Orchard Software acquisition broadens reach into veterinary and other reference labs, creating cross-sell opportunities for the Clinisys platform and its AI-enabled CLS solutions across new segments and regions.

AI driven workflows CLS v2025.2 with CLS CARE AI assistant and hands-free AI reporting via G2 Speech; integration with Azure ML; opportunity to sell AI-enabled automation to high-throughput clinical pathology and genomics labs, increasing throughput and standardization while reducing manual tasks.

Strategic partnerships Active partnerships and channel strategies (Right Click Info for LATAM/Caribbean; conference sponsorships; WinPath compatibility) indicate a scalable model for entering new markets. Sales plays include region-specific partnerships, local support, and co-marketing to accelerate adoption of the Clinisys platform.

Acquisition expansion Acquiring Orchard Software extends footprint into veterinary and additional reference labs, enabling cross-sell of labs informatics, analytics, and automation across both legacy Clinisys customers and Orchard users, with a unified platform strategy.

Industry engagement Active participation in Bio-IT World and other industry events supports lead generation and brand credibility; leverage joint marketing, case studies, and ecosystem integrations (such as WinPath and G2 Speech) to target labs in genomics, clinical pathology, and CROs.